Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
renal cell carcinoma | EFO_0000376 | D002292 | — |
Expiration | Code | ||
---|---|---|---|
CABOZANTINIB S-MALATE, CABOMETYX, EXELIXIS INC | |||
2028-09-17 | ODE-375 | ||
2026-01-14 | ODE-227 | ||
2024-09-17 | I-873 | ||
2024-01-22 | I-854 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Cabozantinib S-Malate, Cabometyx, Exelixis Inc | |||
9724342 | 2033-07-09 | DP | |
11298349 | 2032-02-10 | DP | |
10034873 | 2031-07-18 | U-2488 | |
10039757 | 2031-07-18 | U-1480 | |
8877776 | 2030-10-08 | DS, DP | U-1617, U-3225 |
11091439 | 2030-01-15 | DP | |
11091440 | 2030-01-15 | DP | |
11098015 | 2030-01-15 | U-1220, U-1480, U-1617, U-2488, U-3225 | |
7579473 | 2026-08-14 | DS, DP | |
8497284 | 2024-09-24 | U-1220, U-1480, U-2488 | |
Cabozantinib S-Malate, Cometriq, Exelixis | |||
9717720 | 2032-02-10 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Renal cell carcinoma | D002292 | EFO_0000376 | — | 22 | 40 | 10 | 3 | 22 | 92 |
Carcinoma | D002277 | — | C80.0 | 13 | 51 | 8 | 1 | 14 | 80 |
Neoplasms | D009369 | — | C80 | 15 | 20 | 4 | 1 | — | 38 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 9 | 24 | 2 | 1 | 2 | 33 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 8 | 19 | 2 | 1 | 2 | 28 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 5 | 10 | 5 | 3 | 6 | 28 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | 4 | 6 | 5 | 2 | 3 | 20 |
Thyroid diseases | D013959 | — | E00-E07 | 1 | 5 | 4 | 2 | 3 | 15 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 6 | 6 | — | 1 | — | 13 |
Papillary thyroid cancer | D000077273 | — | — | 1 | 3 | 3 | 1 | 1 | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 7 | 13 | 3 | — | 1 | 23 |
Non-small-cell lung carcinoma | D002289 | — | — | 8 | 13 | 1 | — | — | 20 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 2 | 12 | 1 | — | 1 | 15 |
Lung neoplasms | D008175 | — | C34.90 | 2 | 10 | 1 | — | — | 12 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 4 | 5 | 2 | — | — | 11 |
Adenocarcinoma | D000230 | — | — | 2 | 9 | 1 | — | — | 11 |
Osteosarcoma | D012516 | — | — | 2 | 6 | 1 | — | — | 8 |
Urinary bladder neoplasms | D001749 | — | C67 | 1 | 5 | 1 | — | — | 7 |
Transitional cell carcinoma | D002295 | — | — | 3 | 3 | 1 | — | — | 7 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | 1 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sarcoma | D012509 | — | — | 3 | 10 | — | — | — | 12 |
Urologic neoplasms | D014571 | — | C64-C68 | 5 | 7 | — | — | — | 11 |
Recurrence | D012008 | — | — | 2 | 9 | — | — | 1 | 11 |
Colorectal neoplasms | D015179 | — | — | 6 | 4 | — | — | 1 | 10 |
Melanoma | D008545 | — | — | 4 | 6 | — | — | 1 | 10 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 4 | — | — | — | 7 |
Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | 3 | — | — | — | 6 |
Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | 5 | — | — | — | 6 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 2 | — | — | — | 5 |
Multiple myeloma | D009101 | — | C90.0 | 4 | 2 | — | — | 1 | 5 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloid leukemia acute | D015470 | — | C92.0 | 2 | — | — | — | 1 | 3 |
Leukemia | D007938 | — | C95 | 1 | — | — | — | 1 | 2 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 1 | 2 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | 1 | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | — | — | — | — | 2 |
Malignant mesothelioma | D000086002 | — | — | 2 | — | — | — | — | 2 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | 1 | 2 |
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 1 | 1 |
Drug common name | Cabozantinib |
INN | cabozantinib |
Description | Cabozantinib is a dicarboxylic acid diamide that is N-phenyl-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide in which the hydrogen at position 4 on the phenyl ring is substituted by a (6,7-dimethoxyquinolin-4-yl)oxy group. A multi-tyrosine kinase inhibitor, used (as its malate salt) for the treatment of progressive, metastatic, medullary thyroid cancer. It has a role as a tyrosine kinase inhibitor and an antineoplastic agent. It is a member of quinolines, an organofluorine compound, an aromatic ether and a dicarboxylic acid diamide. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC |
PDB | — |
CAS-ID | 849217-68-1 |
RxCUI | — |
ChEMBL ID | CHEMBL2105717 |
ChEBI ID | 72317 |
PubChem CID | 25102847 |
DrugBank | DB08875 |
UNII ID | 1C39JW444G (ChemIDplus, GSRS) |